课题基金 / 基金详情

PHARMACOKINETICS & TOLERANCE OF GANCICLOVIR IN HIV INFECTED CHILDREN

PHARMACOKINETICS & TOLERANCE OF GANCICLOVIR IN HIV INFECTED CHILDREN
药代动力学
批准号：
6274832
负责人：
JOSEPH CHURCH
金额：
$3.67万
依托单位：
UNIVERSITY OF SOUTHERN CALIFORNIA
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274832
关键词：
AIDS therapy HIV infections Herpesviridae disease adolescence (12-20) child (0-11) clinical research clinical trials cytomegalovirus drug administration rate /duration drug adverse effect drug screening /evaluation drug tolerance ganciclovir human immunodeficiency virus human subject human therapy evaluation opportunistic infections oral administration pediatric AIDS pediatric pharmacology pharmacokinetics

项目摘要

项目成果

JOSEPH CHURCH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Individuals between two weeks to twenty years of age who have an HIV and cytomegalovirus are enrolled in this study to evaluate the safety and side effects of a new oral medication, ganciclovir. The purpose of this study is to determine if an oral form of ganciclovir can be tolerated when given for 24 weeks to HIV infected infants and children with CMV infection and to determine the maximum tolerable dose and side effects of oral ganciclovir.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IN VIVO ASSESSMENT OF CLINICALLY RELEVANT AUTOANTIBODIES IN IVIG PREPARATIONS
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VIRUS VACCINE IN CHILDREN W/HIV
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VIRUS VACCINE IN CHILDREN W/HIV
SAFETY AND IMMUNOGENICITY OF OKA/MERCK VARICELLA VACCINE
海外基金